| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Leptin R | Human Leptin R / CD295 Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $330.00 100ug | |||
| Leptin R | Avitag LER-H82E3 | Biotinylated Human Leptin R Protein, His,Avitag™ | Human | HEK293 | ![]() | SDS-PAGE | $368.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Mibavademab | REGN-4461 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Amenorrhea; Lipodystrophy, Congenital Generalized; Lipodystrophy, Familial Partial; Monogenic obesity; Obesity | Details |
| RG-6436 | RG6436; RG-6436 | Phase 1 Clinical | Enterprise Therapeutics Ltd, Genentech Inc | Urinary Tract Infections | Details |
| ERX-1000 | ERX-1000 | Phase 1 Clinical | ERX Pharmaceuticals Inc | Obesity | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Metreleptin | KTR-103; AC-164594 | Approved | Amylin Pharmaceutical, Astrazeneca Plc, Bristol-Myers Squibb Company | Metreleptin [SHIONOGI], Myalepta | Japan | Lipodystrophy | Shionogi & Co Ltd | 2013-03-25 | Diabetes Mellitus; Diabetes Mellitus, Type 1; HIV Infections; Hyperlipidemias; Insulin Resistance; Lipodystrophy; Lipodystrophy, Congenital Generalized; Lipodystrophy, Familial Partial; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Obesity; Overweight | Details |
